HOTEL101 PROGRESSES TOWARDS NASDAQ LISTING
U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE SINGAPORE, June 2, 2025…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…
DoorDash Announces Closing of Upsized $2.75 Billion Offering of 0% Convertible Senior Notes
Opportunistic capital raise with proceeds used to enhance strategic flexibility A portion…
